Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Poly(A)-specific ribonuclease PNLDC1 is a deadenylase enzyme that specifically trims 3′ poly(A) tails from RNA and is structurally related to poly(A)-specific ribonuclease (PARN), but forms a distinct evolutionary group[1]. It is selectively expressed in mammalian embryonic stem cells, testes, and germline cells, where it plays a crucial role in the maturation of piwi-interacting RNAs (piRNAs) by trimming precursor piRNA 3′ ends, thereby enabling transposon silencing and maintaining genome integrity in the germline[1][2][3][4]. PNLDC1 is essential for spermatogenesis, with its loss causing defective piRNA processing and spermatogenic failure leading to male infertility (SPGF57)[2][3][4][5]. The enzyme's activity is tightly regulated via epigenetic mechanisms, is predominantly cytoplasmic (localized to ER), and is involved in pathways controlling cell cycle, chromatin assembly, and reprogramming during early development[1]. Currently, there are no known direct drugs or small molecules that target PNLDC1, nor is it described as a clinically actionable biomarker, but its disruption is a notable cause of genetic azoospermia[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Poly(A)-specific ribonuclease PNLDC1 (PNLDC1).